Toll样受体9激动剂与依维莫司联合使用可干扰肾细胞癌的生长和血管生成活性。
Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma.
作者信息
Rosa Roberta, Damiano Vincenzo, Formisano Luigi, Nappi Lucia, Marciano Roberta, Veneziani Bianca Maria, De Placido Sabino, Bianco Roberto
机构信息
Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica; Università di Napoli "Federico II"; Naples, Italy.
出版信息
Oncoimmunology. 2013 Aug 1;2(8):e25123. doi: 10.4161/onci.25123. Epub 2013 May 28.
The mTOR inhibitor everolimus is currently approved for the treatment of renal cell carcinoma (RCC) and several Toll-like receptor 9 (TLR9) agonists, including immunomodulatory oligonucleotides (IMOs), have been tested for their therapeutic potential against advanced RCC. However, no clinical trials investigating the combination of mTOR inhibitors with TLR9 agonists in RCC patients have been performed to date. Our results may pave the way to translate this combinatorial approach to the clinical setting.
mTOR抑制剂依维莫司目前已被批准用于治疗肾细胞癌（RCC），并且几种Toll样受体9（TLR9）激动剂，包括免疫调节寡核苷酸（IMO），已经针对其对晚期RCC的治疗潜力进行了测试。然而，迄今为止，尚未进行过关于在RCC患者中联合使用mTOR抑制剂与TLR9激动剂的临床试验。我们的结果可能为将这种联合方法转化到临床应用中铺平道路。
Zotero 插件